A Phase 3 interventional study of Afimkibart in Moderately to Severely Active Crohns Disease, sponsored by Hoffmann-La Roche. Recruiting at 19 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Crohn Disease by Hoffmann-La Roche — 3 open to participants now, 4 under way, 3 of them phase 3. Crohn Disease · Hoffmann-La Roche.
Among the 10 studies in Crohn Disease by Hoffmann-La Roche, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 3, and was the 10th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →3 of the 10 studies in Crohn Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 24 more countries
Ages 16–80
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 35 more countries
Ages 16–80
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 122 across the 10 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Crohn Disease by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05910528Hoffmann-La RocheAfimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Crohn Disease by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.
Drug: Afimkibart
Participants will receive Afimkibart IV followed by Afimkibart SC.
Drug: Afimkibart
Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
Also known as: RO7790121, PF-06480605, RVT-3101
Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)
Time frame: At Week 52
Percentage of Participants With Endoscopic Response
Time frame: At Week 52
Percentage of Participants With Clinical Remission
Time frame: At Week 12 and Week 52
Percentage of Participants With Clinical Response
Time frame: At Week 12 and Week 52
Percentage of Participants With CDAI Remission
Time frame: At Week 12 and Week 52
Change From Baseline in Fecal Calprotectin
Time frame: Baseline, Week 12 and Week 52
Change From Baseline in Mucosal Inflammation Noninvasive Index (MINI) Score
Time frame: Baseline, Week 12 and Week 52
Percentage of Participants With Endoscopic Remission
Time frame: At Week 52
Percentage of Participants With Corticosteroid-Free Clinical Remission
Time frame: At Week 52
Percentage of Participants with Maintenance of Remission
Time frame: At Week 12 and Week 52
Percentage of Participants With Histologic Improvement
Time frame: At Week 52
Percentage of Participants With Ulcer-Free Endoscopy
Time frame: At Week 52
Incidence and Severity of Adverse Events (AEs)
Time frame: Up to Approximately 5.5 Years
Serum Concentration of Afimkibart
Time frame: Up to Approximately 5.5 Years
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Aug 2026 (actual). Primary completion is estimated for May 2030, 45 months after the start.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 45 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afimkibart